Bellco, an Italy-based supplier of hemodialysis and intensive care products, was granted exclusive rights to market Nephros' patented mid-dilution dialysis filters -MD 190, MD 220 - in Canada, Italy, France, Spain and Belgium for the period 1 July 2011 to 31 December 2016.
Bellco will also receive certain additional non-exclusive distribution rights during the license period in the UK and Greece and, upon Bellco’s request, elsewhere in Europe where Nephros is not then selling the mid-dilution technology, and, upon Bellco’s request and Nephros’ approval, in other markets.
The company will pay to Nephros EUR1.85m in three installments.
It will also pay a royalty of EUR4.50 per unit up to 103,000 units and EUR4.00 per unit above 103,000 units sold per year, for the period January 1 2015 until 31 December 2016.
Nephros acting CEO Paul Mieyal said the license agreement will allow Bellco to leverage its sales and marketing expertise to increase sales of the mid-dilution technology in the licensed territories."
Bellco CEO Stefano Rimondi said the mid-dilution dialyzer is an important product for patients with end-stage renal disease, and Bellco looks forward to the opportunity to manufacture and market this innovative product under its own label.